John Rim, Samsung Biologics CEO (Samsung/PR Newswire)
January 27, 2023 03:54 PM ESTUpdated February 2, 12:28 PM
Pharma
Manufacturing

Up­dat­ed: Sam­sung Bi­o­log­ics spells out ex­pan­sion plans in South Ko­rea and US

Tyler Patchen

News Reporter

The CD­MO arm of one of South Ko­rea’s largest con­glom­er­ates has post­ed its year-end re­sults and plans for 2023, which in­clude new con­struc­tion.

Sam­sung Bi­o­log­ics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times